MD

Pediatrix Medical Group, Inc. - Q1 2002 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2002. Pediatrix Medical Group, Inc. operates as a physician group practice specializing in neonatal and pediatric care. The company continues to expand through acquisitions, including the integration of Magella Healthcare Corporation (acquired May 2001) and additional physician groups acquired in Q1 2002 and subsequent to the quarter end.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 67.8% year-over-year. Approximately 78.8% of this increase ($34.2 million) was driven by new units from acquisitions, while same-unit revenue grew 14.3% due to improved collections, price increases, and higher patient days.
• Profitability: Net income increased 274% to $13.5 million. Operating income rose 217.2% to $22.2 million.
• Expense Management: Practice salaries increased 63.5% due to new staff from acquisitions. General and administrative expenses rose 44.1%, partially due to a $1.3 million settlement cost related to a Colorado Medicaid investigation.
• Accounting Changes: Depreciation and amortization decreased 59.1% to $1.5 million following the adoption of FAS 142, which eliminated goodwill amortization. This also contributed to a lower effective tax rate (39.0% vs. 45.0% in 2001).
• Liquidity: Cash and cash equivalents increased by $9.0 million to $36.6 million, driven by operating cash flow ($4.6 million) and proceeds from stock issuance ($7.9 million).

Outlook, Risks, and Contingencies

• Acquisitions: The company completed one acquisition during the quarter ($1.8 million) and three additional acquisitions post-quarter end totaling approximately $16.4 million.
• Legal Settlements: A securities class action lawsuit was settled for $12.0 million (approved May 3, 2002). A Colorado Medicaid investigation was settled for $1.3 million in April 2002.
• Ongoing Investigations: A TRICARE investigation regarding billing practices remains active. The company anticipates continued audits and inquiries from government agencies, though it believes these will not have a material adverse effect.
• Management Changes: A succession plan was announced to transfer CEO duties from Dr. Roger J. Medel to Mr. Kristen Bratberg effective January 1, 2003.
• Capital Resources: Management expects funds from operations and the $100 million line of credit to be sufficient for working capital and capital expenditures for the next 12 months.

Investor Verification Checklist

• Verify the status and potential financial impact of the ongoing TRICARE investigation and other state Medicaid inquiries.
• Confirm the integration progress and revenue contribution of the Magella Healthcare Corporation merger and recent Q1 2002 acquisitions.
• Monitor the impact of the FAS 142 goodwill impairment testing process, which is ongoing for the 2002 fiscal year.
• Review the terms of the new professional liability insurance coverage effective May 1, 2002, specifically regarding self-insured retention levels.
• Assess the dilution impact of the increased share count (26.7 million outstanding) resulting from the merger and stock option exercises.